Chk1 Monoclonal Antibody (DCS-310), Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | PIMA191087-Each-of-1 | In Stock | ₹ 53,311.00 |
PIMA191087 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 53,311.00
GST (18%): ₹ 9,595.98
Total Price: ₹ 62,906.98
Antigen
Chk1
Classification
Monoclonal
Concentration
0.2 mg/mL
Formulation
PBS with 0.2% BSA and 0.09% sodium azide; pH 7.2
Gene Accession No.
O14757, O35280, Q91ZN7
Gene Symbols
Chek1
Immunogen
Recombinant full length protein (Human).
Quantity
100 μg
Primary or Secondary
Primary
Target Species
Human, Mouse, Rat
Product Type
Antibody
Isotype
IgG3
Applications
Immunohistochemistry (Paraffin), Immunoprecipitation, Western Blot
Clone
DCS-310
Conjugate
Unconjugated
Gene
Chek1
Gene Alias
C85740; Cell cycle checkpoint kinase; checkpoint kinase 1; checkpoint kinase 1 homolog; checkpoint kinase-1; Checkpoint, S. pombe, homolog of, 1; CHEK1; CHK1; CHK1 checkpoint homolog; Chk1-S; homolog of Chk1-S; HRD1 Protein; rad27; rad27 homolog; serine/threonine protein kinase CHK1; serine/threonine-protein kinase Chk1; Synoviolin; YBR1742; YBR274W
Host Species
Mouse
Purification Method
Protein A
Regulatory Status
RUO
Gene ID (Entrez)
1111, 12649, 140583
Content And Storage
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Form
Liquid
Related Products
Description
- Heat in a microwave oven, twice for 10 minutes in citrate buffer, pH 6.5
- CHEK1 (CHK1) is a serine/threonine protein kinase involved in preventing replication when DNA integrity is compromised
- CHK1 is a key mediator in the DNA damage-induced checkpoint network
- CHK1 is an evolutionarily conserved protein kinase that functions to ensure genomic integrity upon genotoxic stress
- When the G2 or S checkpoint is abrogated by the inhibition of CHK1, p53-deficient cancer cells undergo mitotic catastrophe and eventually apoptosis, whereas normal cells are still arrested in the G1 phase
- Thus, CHK1 inhibitors can preferentially potentiate the efficacy of DNA damaging agents in cancer cells, and Chk1 is an attractive therapeutic target for cancer treatment, especially since approximately 50% of all human cancers are p53-deficient.